Download PDF
Thromb Haemost 2002; 88(04): 542-544
DOI: 10.1055/s-0037-1613254
Commentary
Schattauer GmbH

Cost Trends in the Treatment for Hemophilia: Another View

Stephen D. Kletter
1   Charles River Associates, Washington, DC, USA
,
Peter J. Rankin
1   Charles River Associates, Washington, DC, USA
› Author Affiliations
Further Information

Publication History

Received 26 April 2002

Accepted 26 May 2002

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Rogoff EG. et al. The Upward Spiral of Drug Costs: A Longitudinal Study of Drugs Used in the Treatment of Hemophilia. Thromb Haemost 2002; 88: 545-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Marketing Research Bureau Inc. The Plasma Fractions Market in the United States. 2000
    PubMedGoogle Scholar
  • 3 Marketing Research Bureau Inc. Survey on Hemophilia Care & Price Monitoring, United States – Wave # 11. February 2001
    PubMedGoogle Scholar
  • 4 U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index, All Urban Consumers (CPI-U). April 16, 2002
    PubMedGoogle Scholar
  • 5 Medical and Scientific Advisory Council (MASAC), National Hemophilia Foundation. MASAC Recommendation # 114. April 3, 2001
    PubMedGoogle Scholar
  • 6 Reinhardt U. The New York Times, Op-Ed article. January 3, 2001
    PubMedGoogle Scholar
  • 7 Stecklow S. Playing Safe: ‘Mad Cow’ Fear Leads U.K. to Destroy Parts of All Donated Blood. The Wall Street Journal November 25, 1998; A-1.
    PubMedGoogle Scholar